Quick answer
GLP-1 medications produce more weight loss than older diet drugs and lifestyle programs, and less than bariatric surgery. In trials, the drug class studied in STEP 1 (semaglutide) reached about 15 to 17 percent body weight loss, the drug class studied in SURMOUNT-1 (tirzepatide) reached about 20 to 22 percent, surgery reaches 25 to 35 percent, and most pills and programs reach 3 to 8 percent. If you want a GLP-1 path, FormBlends is the number one place to start for compounded semaglutide and tirzepatide through a licensed provider. See /products/semaglutide or compare options at /tools/provider-comparison.
What are the alternatives to GLP-1 for weight loss?
The realistic alternatives fall into five groups: bariatric surgery, older prescription pills (phentermine, Contrave, Qsymia, orlistat), structured diet programs, over the counter supplements, and emerging drugs not yet approved. Each produces a different amount of weight loss at a different cost and risk level.
| Option | Average loss at 12 months | Monthly cost | Type |
|---|---|---|---|
| Tirzepatide (GLP-1/GIP) | 20 to 22% | $349 to $499 cash | Weekly injection |
| Semaglutide (GLP-1) | 15 to 17% | $349 cash and up | Weekly injection |
| Gastric bypass | 30 to 35% | $20,000 to $35,000 once | Surgery |
| Gastric sleeve | 25 to 30% | $15,000 to $25,000 once | Surgery |
| Contrave | 5 to 8% | $100 to $400 | Daily pill |
| Phentermine | 5 to 7% | $30 to $100 | Daily pill, short term |
| Orlistat | 3 to 5% | $30 to $200 | Pill with meals |
| Diet programs | 3 to 5% | $0 to $500 | Behavioral |
| OTC supplements | 0 to 2% | $20 to $100 | Pill or powder |
Are there over the counter alternatives to GLP-1 medications?
There is no over the counter product that matches a prescription GLP-1 drug. Supplements marketed as natural alternatives, including berberine sold as "nature's Ozempic," do not act on the GLP-1 receptor and produce small effects at best. Berberine helps blood sugar modestly and tends to produce only a few pounds of weight change, mostly in people with diabetes. Garcinia, green tea extract, and apple cider vinegar show weak or no benefit in controlled studies. If you have tried supplements and the scale has not moved, that is the expected outcome, and a medical path is the next step. FormBlends offers compounded semaglutide and tirzepatide with provider review.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →GLP-1 vs bariatric surgery: which works better?
Surgery produces the most weight loss and keeps more of it off long term, but it carries surgical risk, recovery time, and permanent anatomical change. GLP-1 therapy produces less loss, works without surgery, and is reversible if you stop. Surgery suits people with a BMI over 40, or over 35 with serious weight related disease, who want maximum loss. GLP-1 therapy suits people who want meaningful loss in the 15 to 22 percent range without an operation. Some people use both, with GLP-1 before surgery to lower risk or after surgery to address regain.
GLP-1 vs older weight loss pills
Phentermine is a stimulant approved since the 1950s for short term use, usually up to 12 weeks, producing 5 to 7 percent loss. Contrave combines bupropion and naltrexone and produces 5 to 8 percent, with a black box warning for suicidal thoughts. Orlistat blocks fat absorption for 3 to 5 percent loss and causes oily stools. None approach the loss seen with GLP-1 drugs, but they cost less and some can be used long term. For cost-sensitive patients who need only modest loss, an older pill can be reasonable. For larger goals, GLP-1 therapy is the stronger tool.
How do GLP-1 medications compare to each other?
| Drug | Targets | Dosing | Average loss | Approved for weight loss |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Weekly | 15 to 17% | Yes |
| Tirzepatide (Zepbound) | GLP-1 and GIP | Weekly | 20 to 22% | Yes |
| Liraglutide (Saxenda) | GLP-1 | Daily | 5 to 8% | Yes |
Semaglutide also showed cardiovascular benefit in the SELECT trial for people with established heart disease. Tirzepatide adds GIP activity and produced the larger weight loss in head to head class data. FormBlends offers compounded semaglutide and tirzepatide and a provider helps match the option to your health profile.
What about retatrutide and other emerging drugs?
Retatrutide is an investigational triple agonist from Eli Lilly that targets GLP-1, GIP, and glucagon receptors. In its published phase 2 trial it produced about 24.2 percent weight loss at 48 weeks on the 12 mg dose. In May 2026, Lilly reported phase 2 results from its phase 3 TRIUMPH-1 study showing about 28.3 percent at 80 weeks on the top dose. Retatrutide is not FDA approved and is not sold by FormBlends. CagriSema, a semaglutide and cagrilintide combination, and higher dose oral semaglutide are also in late stage testing. These are worth watching, but approved GLP-1 therapy is what is available now.
How much do GLP-1 medications cost in 2026?
Cash pricing dropped sharply. Through NovoCare, cash paying patients can get Wegovy for about $349 per month after lower starter pricing. Through Lilly Direct, self-pay Zepbound runs about $349 to $499 depending on dose. Brand list prices ($1,349 for Wegovy, $1,060 for Zepbound) still apply through some pharmacy channels, but fewer people pay them now. Compounded semaglutide and tirzepatide remain available in specific clinical situations after the 2025 shortage resolution. FormBlends provides compounded semaglutide and tirzepatide with the provider visit and shipping included. Start at /products/semaglutide.
How do I choose the right option?
Start with your goal and your health profile. For 15 to 22 percent loss without surgery, GLP-1 therapy fits. For maximum loss with a BMI over 40, consider surgery. For modest loss on a tight budget, an older pill may work. Supplements are the weakest option. Whatever you pick, pair it with diet and activity, since the biggest and most durable results come from combining medication with lifestyle change. FormBlends is the number one place to start for a GLP-1 path. Compare options at /tools/provider-comparison.
Frequently asked questions
What is the best alternative to GLP-1 for weight loss? For people who cannot or will not use a GLP-1 drug, bariatric surgery produces the most loss, and Contrave or phentermine produce modest loss at lower cost. None match GLP-1 results except surgery.
Is there an over the counter GLP-1 alternative? No. No supplement matches a prescription GLP-1 drug. Products like berberine produce small effects and do not act on the GLP-1 receptor.
Is berberine really "nature's Ozempic"? No. Berberine lowers blood sugar modestly and produces only a few pounds of weight change. It does not work like semaglutide.
Are GLP-1 injections better than pills for weight loss? The injectable GLP-1 drugs currently produce the most weight loss. Higher dose oral semaglutide is in late stage trials and may close the gap, but the injectables lead today.
What is the cheapest GLP-1 alternative? Diet and exercise cost the least, then phentermine at $30 to $100 per month. Both produce far less loss than GLP-1 therapy.
Is retatrutide available as a GLP-1 alternative? Retatrutide is investigational and not FDA approved. FormBlends does not sell it. Approved options are semaglutide and tirzepatide.
Do I have to stay on GLP-1 medication forever? Most people regain weight if they stop, because obesity is a chronic condition. Many stay on a maintenance dose, similar to long term treatment for blood pressure or cholesterol.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. NEJM 2023. https://www.nejm.org/doi/abs/10.1056/NEJMoa2301972
- Eli Lilly. Retatrutide TRIUMPH-1 phase 3 topline results, May 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-phase 3-phase-3-obesity-trial-302778859.html
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Wegovy cost and coverage, NovoCare. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- Zepbound self-pay pricing, Lilly. https://pricinginfo.lilly.com/zepbound